Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 229 participants.

Also called NCT04720534

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 229 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04720534
Other papers using this trial's data
  • Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial JAMA cardiology, 2024-07-01 DOI, PubMed 38583092, PMC11000138 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Canada, Germany, Hungary, Netherlands, New Zealand, Poland (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04720534. Randomized; quadruple masking; primary purpose treatment. Start 2021-05-31 (actual); primary completion 2023-03-09 (actual). Results posted on 2026-03-24.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia
Acronym
SHASTA-2
Condition
Severe Hypertriglyceridemia
Intervention (Drug)
ARO-APOC3
Intervention (Drug)
Placebo
Lead sponsor
Arrowhead Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct04720534
Content hash
dc680f9fe156249e0d277496c4dc9dca4eaf2fd20a70a0dc0ee637ffa51923a5